The White House has released a plan to ensure that Congress approves the coronivirus vaccination rollout and that all Americans have access to the lifesaving vaccine by mid-January, according to a draft of the White Houses plan released Tuesday.
The plan was made public by the WhiteHouse press office in response to a question about whether the administration has the votes in the House and Senate to pass the coronovirus vaccination plan and if the president will sign the bill into law.
The president is expected to sign the coronAVISA Act into law by the end of the year.
But he will need Congress to pass it before that date, which would be on Feb. 7.
The White House said it is working to get the Senate to approve the coronavia vaccine by the early-March deadline.
The draft is not finalized, but the draft was developed in coordination with the Whitehouse, HHS and the Centers for Disease Control and Prevention, the White house said in a statement.
The bill also includes $4.8 billion for the White Helmets coronaviral rescue operation, and $8 billion to expand and expand access to lifesaving vaccines for children and families.
The measure also expands the National Vaccine Adoption Plan, which provides a $2.4 billion federal matching grant to states for vaccines for the coronaviirus pandemic.
The coronaviruses coronavira and coronavirin are being treated by several coronavire vaccine manufacturers and companies, including GlaxoSmithKline (GSK), Johnson & Johnson (JNJ) and GlaxosmithKline Corp. (GSX), and a new manufacturer, Vioxx Inc. The companies have not yet been announced.
The White house is expected later this year to announce whether any of these vaccines will be licensed.
The legislation also provides for the use of a private, state-run vaccine provider for the pandemic, to be known as a “vaccine-on-demand” program, as opposed to a federally administered vaccine program.
This type of program is often used by health care providers to provide vaccines in a more timely manner, but it has not been fully developed.
The public health benefits of this type of vaccine-on, demand-provide program have been widely studied, the administration said.
The administration also plans to expand the number of coronavirotic virus vaccines to more than 3 million, and the White HOUSE is also planning to release new data on the effectiveness of coronavia and coronavi vaccines.
The Trump administration also has promised to make the public health gains from the coronava virus vaccine more visible by launching a $500 million online video series to highlight the efficacy of the vaccines.
The goal of the online video project is to provide information about the effectiveness and safety of the vaccine, the president said in March.
The presidential announcement comes days after a new coronavisc virus vaccine, which is being developed by Johnson &s; Johnson, was shown to be safe, effective and inexpensive in the first trial of the drug.
The company said it will begin distributing the drug to hospitals and doctors in the U.S. next month.
It is unclear if it will receive FDA approval to sell the vaccine or whether it will go through the usual FDA review process.
